An interventional study of Cala TWO in Essential Tremor, sponsored by Cala Health, Inc.. Completed at 32 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.
Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.
Among the 146 studies in Essential Tremor with a site in United States, this one is the 6th largest by enrollment of the 104 interventional ones that give a count, is one of 5 that started in 2018, is one of 60 with no phase, and was the 76th registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:
Encora, Inc. · Sites in United States
Ages 18+
AbbVie · Sites in United States, Canada
Ages 18–85
University of California, Los Angeles · Sites in United States
Ages 18–90
CND Life Sciences · Sites in United States
Ages 50–85
Boston University Charles River Campus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 3 5 · Phase 4 5
First in 2000; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 30 across the 104 interventional studies, 81 across the 41 observational. Of the 86 that completed or were terminated, 39 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 146 have an industry lead sponsor. The 10 most frequent:
Cala Health, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Cala Health, Inc. has 5 studies filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
13 of the studies in Essential Tremor with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03778060Mayo ClinicLong-Term Transcutaneous Stimulation and Essential Tremor: A PET Study | 2026-12 |
| NCT07599592University of California, Los AngelesOpen Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor | 2026-12-31 |
| NCT07428447CND Life SciencesAnalysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | 2027-02 |
| NCT04286308Massachusetts General HospitalCortical-Basal Ganglia Speech Networks | 2027-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 146 studies in Essential Tremor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multi-center, single-arm, non-significant risk study designed to evaluate the Cala TWO device. Subjects will be screened for eligibility and fitted with a Cala TWO device. Subjects will wear the device at home for a period of 3 months, during which they will be asked to stimulate their dominant hand twice a day. The stimulation amplitude will be based on each subject's stimulation threshold. Subjects will have in clinic assessments at enrollment, month 1 and 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willing to comply with study protocol requirements including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two 40-minute stimulation sessions daily, separated by at least two hours
Device: Cala TWO
Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score
Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.
Time frame: Baseline to 3-months
Bain & Findley Activities of Daily Living (ADL) Scale Subset Score
Bain \& Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.
Time frame: Baseline to 3-months
Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions
Subjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.
Time frame: Average change in tremor power over 3-month study period
| Milestone | Cala TWO |
|---|---|
| Started | 263 |
| Completed | 205 |
| Not completed | 58 |
Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.
| score on a scale | Cala TWO |
|---|---|
| Baseline | 12.6 ± 2.7 |
| Final Visit | 9.8 ± 3.5 |
| Change | -2.8 ± 2.8 |
Bain \& Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.
| score on a scale | Cala TWO |
|---|---|
| Baseline | 18.4 ± 3.8 |
| Final Visit | 13.4 ± 4.4 |
| Change | -4.98 ± 4.3 |
Subjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.
| (m/s^2)^2 | Cala TWO |
|---|---|
| Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions | -0.8 ± 3.7 |
Collected over Up to 3 months since baseline testing. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cala TWO | 1/263 (0.4%) | 5/263 (1.9%) | 47/263 (17.9%) |
| Event | Cala TWO |
|---|---|
| Initial or prolonged hospitalizationGeneral disorders | 5/263 |
| Event | Cala TWO |
|---|---|
| Significant and persistent skin irritationSkin and subcutaneous tissue disorders | 14/263 |
| Sore/LesionSkin and subcutaneous tissue disorders | 10/263 |
| Significant discomfortSkin and subcutaneous tissue disorders | 6/263 |
| Electrical burnsSkin and subcutaneous tissue disorders | 6/263 |
| Minor Skin IrritationSkin and subcutaneous tissue disorders | 6/263 |
| Other isolated eventsSkin and subcutaneous tissue disorders | 5/263 |
| Electric shock sensation while using deviceSkin and subcutaneous tissue disorders | 3/263 |
| Worsening of tremorNervous system disorders | 2/263 |
| Age, Continuous(years) | Cala TWO |
|---|---|
| Mean | 69.6 ± 10.1 |
| Sex: Female, Male(Participants) | Cala TWO |
|---|---|
| Female | 137 |
| Male | 126 |
| Ethnicity (NIH/OMB)(Participants) | Cala TWO |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 253 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Cala TWO |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 237 |
| More than one race | 3 |
| Unknown or Not Reported | 5 |
| Region of Enrollment(participants) | Cala TWO |
|---|---|
| United States | 263 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in May 2019, 5 months.
Results were first posted in Oct 2023, 4 years 4 months after primary completion.
Of 95 interventional studies with no phase under Essential Tremor, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 93. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cala Health, Inc.